In vivo binding of a tau imaging probe, [ 11 C]PBB3, in patients with progressive supranuclear palsy.

Autor:	Endo H; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.; Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan., Shimada H; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan., Sahara N; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan., Ono M; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan., Koga S; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA., Kitamura S; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.; Department of Psychiatry, Nara Medical University, Kashihara, Japan., Niwa F; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.; Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan., Hirano S; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.; Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan., Kimura Y; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan., Ichise M; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan., Shinotoh H; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.; Neurology Chiba Clinic, Chiba, Japan., Zhang MR; Department of Radiopharmaceuticals Development, Clinical Research Cluster, NIRS, QST, Chiba, Japan., Kuwabara S; Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan., Dickson DW; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA., Toda T; Department of Neurology, University of Tokyo Graduate School of Medicine, Tokyo, Japan., Suhara T; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan., Higuchi M; Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Chiba, Japan.
Jazyk:	angličtina
Zdroj:	Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2019 May; Vol. 34 (5), pp. 744-754. Date of Electronic Publication: 2019 Mar 20.
DOI:	10.1002/mds.27643
Abstrakt:	Background: [ 11 C]pyridinyl-butadienyl-benzothiazole 3 is a PET imaging agent designed for capturing pathological tau aggregates in diverse neurodegenerative disorders, and would be of clinical utility for neuropathological investigations of PSP. Objectives: To explore the usefulness of [ 11 C]pyridinyl-butadienyl-benzothiazole 3/PET in assessing characteristic distributions of tau pathologies and their association with clinical symptoms in the brains of living PSP patients. Methods: We assessed 13 PSP patients and 13 age-matched healthy control subjects. Individuals negative for amyloid β PET with [ 11 C]Pittsburgh compound B underwent clinical scoring, MR scans, and [ 11 C]pyridinyl-butadienyl-benzothiazole 3/PET. Results: There were significant differences in binding potential for [ 11 C]pyridinyl-butadienyl-benzothiazole 3 between PSP patients and healthy control subjects (P = 0.02). PSP patients exhibited greater radioligand retention than healthy control subjects in multiple brain regions, including frontoparietal white matter, parietal gray matter, globus pallidus, STN, red nucleus, and cerebellar dentate nucleus. [ 11 C]pyridinyl-butadienyl-benzothiazole 3 deposition in frontoparietal white matter, but not gray matter, was correlated with general severity of parkinsonian and PSP symptoms, whereas both gray matter and white matter [ 11 C]pyridinyl-butadienyl-benzothiazole 3 accumulations in the frontoparietal cortices were associated with nonverbal cognitive impairments. Autoradiographic and fluorescence labeling with pyridinyl-butadienyl-benzothiazole 3 was observed in gray matter and white matter of PSP motor cortex tissues. Conclusions: Our findings support the in vivo detectability of tau fibrils characteristic of PSP by [ 11 C]pyridinyl-butadienyl-benzothiazole 3/PET, and imply distinct and synergistic contributions of gray matter and white matte tau pathologies to clinical symptoms. [ 11 C]pyridinyl-butadienyl-benzothiazole 3/PET potentially provides a neuroimaging-based index for the evolution of PSP tau pathologies promoting the deterioration of motor and cognitive functions. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. (© 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text